Health Trials

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

ConditionSolid Tumors
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMirati Therapeutics Inc.

About this trial

This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.

Eligibility criteria

Qualifiers

Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.

Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.

Disqualifiers

Participant is not eligible for study treatment per the parent study eligibility criteria.

Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.

Participants not receiving clinical benefit from parent study drug as assessed by the investigator.

Trial design

Treatments tested in this trial

  • Adagrasib
  • Pembrolizumab
  • Cetuximab
  • Pemetrexed
  • Docetaxel
  • Irinotecan
  • Leucovorin
  • Oxaliplatin
  • Fluorouracil

Treatment groups

170 Participants
are divided into 10 treatment groups

10

Treatment groups

See each treatment group below.

Locations

100
Australia
Local Institution - 00932065, St LeonardsNew South Wales, Australia
Belgium
Local Institution - 00339000, Ghent Belgium
Canada
Local Institution - 0072V5Z 4E6, VancouverBritish Columbia, Canada
China
Local Institution - 0037100142, BeijingBeijing Municipality, China

Sponsors and collaborators

Mirati Therapeutics Inc.

Lead sponsor

Source ClinicalTrials.gov